FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896700799> ?p ?o ?g. }

• W2896700799 endingPage "viii440" @default.
• W2896700799 startingPage "viii439" @default.
• W2896700799 abstract "Background: Significant survival benefit has been achieved with CIT across multiple tumour types, but only subsets of patients (pts) experience durable response with CIT monotherapy. Efficacious CIT combinations targeting multiple cancer immune escape mechanisms need to be identified to extend clinical benefit to more pts. The MORPHEUS platform includes multiple Phase Ib/II trials designed to identify early signals of safety and activity of CIT combinations. Using a randomised trial design, multiple CIT combination arms are compared with a single standard-of-care control arm. We present 7 tumour type–specific MORPHEUS trials, each evaluating various CIT combinations that simultaneously enhance immune-cell priming and activation, tumour infiltration and/or recognition of tumour cells for elimination. Trial design: The MORPHEUS trials described here are global, open-label, randomised, Phase Ib/II trials enrolling pts with 1 of the following cancers: pancreatic ductal adenocarcinoma (PDAC), gastric or gastro-oesophageal junction cancers (GC/GEJ), hormone receptor-positive or triple-negative breast cancers (HR+/TNBC), non-small cell lung cancer (NSCLC), or colorectal cancer (CRC) (Table). These trials have the flexibility to open new treatment arms with novel CIT combinations as they become available and to close arms that show minimal activity or unacceptable toxicity. Pts experiencing loss of clinical benefit or unacceptable toxicity may be eligible to switch to a different CIT combination arm. Eligibility requires measurable disease per RECIST v1.1. Further eligibility criteria will be provided. Primary endpoints are safety and investigator-assessed ORR per RECIST v1.1. Secondary endpoints include PFS, OS, DCR and DOR. Exploratory biomarkers will also be examined. Clinical trial identification: NCT03193190, NCT03281369, NCT03280563, NCT03424005, NCT03337698. Editorial acknowledgement: Medical writing assistance for this abstract was provided by Steffen Biechele, PhD, of Health Interactions. Legal entity responsible for the study: F. Hoffmann-La Roche AG. Funding: F. Hoffmann-La Roche AG.Table: 1239TiPSummary of Cancer-Type Specific MORPHEUS TrialsCancer TypeCohortNo. of Experimental ArmsaNot all experimental arms may be open at the same time.Countries Currently Targeted for EnrolmentPDAC2L3Germany, South Korea, Spain, United StatesGC and GEJ1L2Germany, South Korea, Spain, Taiwan, United Kingdom, United States2L4HR+ BC2L4France, South Korea, Spain, United Kingdom, United StatesTNBC2L5Australia, France, Germany, South Korea, Spain, United Kingdom, United StatesNSCLC1L2Australia, France, South Korea, Spain, United Kingdom, United States2L+bPatients who have progressed on prior platinum chemotherapy and anti–PD-L1/PD-1 treatment given concurrently or sequentially. CIT, cancer immunotherapy; CRC, colorectal cancer; GC, gastric cancer; GEJ, gastro-oesophageal junction cancer; HR+ BC, hormone receptor–positive breast cancer; NSCLC, non-small cell lung cancer; PD-1, programmed death-1; PDAC, pancreatic ductal adenocarcinoma; PD-L1, programmed death-ligand 1; TNBC, triple-negative breast cancer.5CRC3L2Australia, France, South Korea, Spain, United Kingdom, United Statesa Not all experimental arms may be open at the same time.b Patients who have progressed on prior platinum chemotherapy and anti–PD-L1/PD-1 treatment given concurrently or sequentially. CIT, cancer immunotherapy; CRC, colorectal cancer; GC, gastric cancer; GEJ, gastro-oesophageal junction cancer; HR+ BC, hormone receptor–positive breast cancer; NSCLC, non-small cell lung cancer; PD-1, programmed death-1; PDAC, pancreatic ductal adenocarcinoma; PD-L1, programmed death-ligand 1; TNBC, triple-negative breast cancer. Open table in a new tab Disclosure: I. Chau: Honoraria: Amgen, Gilead Sciences, Lilly, Pfizer, Taiho Pharmaceutical; Consulting or advisory role: Bayer, Bristol-Myers Squibb, Five Prime Therapeutics, Lilly, MSD Oncology, Roche/Genentech, Sanofi; Research funding: Janssen-Cilag (Inst), Lilly (Inst), Merck Serono (Inst), Sanofi (Inst); Travel, accommodations, expenses: Bristol-Myers Squibb, Lilly, Merck Serono, MSD, Sanofi. G.M. Haag: Advisory role: BMS, Taiho, Nordic, Lilly, MSD; Honoraria: Roche, Pfizer; Travel grant: Amgen, Ipsen, BMS; Research funding: Nordic, Taiho Pharmaceuticals. O.E. Rahma: Consulting or advisory role: Celgene, Alcimed, Gfk, Merck, Five Prime Therapeutics, Putnam Associates; Travel, accommodations, expenses: Merck, Clinical Care Options; Honoraria: Merck, Company: Clinical Care Options, MI Bioresearch; Research Funding: Amgen, Merck. D.A. Yardley: Speaker's bureau, Advisory boards: Genentech. B.J. Solomon: Advisory boards: AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Roche/Genentech, Novartis; Honoraria: Bristol-Myers Squibb, AstraZeneca; Grant/research support: Pfizer; Royalty, IP Rights/Patent Holder: Veristrat (Biodesix). Consulting/advisory role (inst): Genentech/Roche, Celgene, Boehringer Ingelheim, AstraZeneca, OncoMed, BerGenBio, Lilly, EMD Serono, Kadmon, Janssen, Mirati Therapeutics, Genmab, Pfizer, AstraZeneca, Sten CentRx, Novartis, Checkpoint Therapeutics, Array BioPharma, Regeneron, Merck, Hengrui Pharmaceutical, Lycera, BeiGene, Tarveda Therapeutics, Loxo, AbbvieBoehringer Ingelheim, Guardant Health, Foundation Medicine, Daiichi Sankyo, Danofi; Research funding to institution: Mersana; Immediate family member: Contract lobbyist: Astellas Pharma, Otsuka. G.A. Vidal: Advisory board: Genentech, Eli Lily, Immunomedics; Sponsored research: PUMA and Celcuit; Speaker: PUMA, AstraZeneca, Novartis, Lilly, Pfizer. P. Schmid: Honoraria: AstraZeneca, Bayer, Boehringer, Celgene, Eisai, Novartis, Pfizer, Puma, Roche/Genentech; Research support/funding: Astellas, AstraZeneca, Medivation, Novartis, Oncogenex, Roche/Genentech (all to instituation). Spouse: Employee: Roche. K. Dimick, S. Mahrus, C. Bleul: Employee: Roche/Genentech. P. Sayyed: Employee and stock: Roche. H. Barak: Employee and stock: Roche/Genentech; Previously employed: Baxalta. E. Cha: Employee and stock: Roche/Genentech. A. Drakaki: Consulting: BMS; Research funds: Kite. All other authors have declared no conflicts of interest." @default.
• W2896700799 created "2018-10-26" @default.
• W2896700799 creator A5008124413 @default.
• W2896700799 creator A5009065617 @default.
• W2896700799 creator A5018500823 @default.
• W2896700799 creator A5019197153 @default.
• W2896700799 creator A5022422153 @default.
• W2896700799 creator A5023282277 @default.
• W2896700799 creator A5025120810 @default.
• W2896700799 creator A5026548827 @default.
• W2896700799 creator A5030332289 @default.
• W2896700799 creator A5033795704 @default.
• W2896700799 creator A5034692104 @default.
• W2896700799 creator A5049294543 @default.
• W2896700799 creator A5053880366 @default.
• W2896700799 creator A5073189857 @default.
• W2896700799 creator A5079047996 @default.
• W2896700799 creator A5079638740 @default.
• W2896700799 creator A5080783554 @default.
• W2896700799 creator A5087491297 @default.
• W2896700799 creator A5089861374 @default.
• W2896700799 creator A5091426116 @default.
• W2896700799 date "2018-10-01" @default.
• W2896700799 modified "2023-10-14" @default.
• W2896700799 title "MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types" @default.
• W2896700799 doi "https://doi.org/10.1093/annonc/mdy288.110" @default.
• W2896700799 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32137119" @default.
• W2896700799 hasPublicationYear "2018" @default.
• W2896700799 type Work @default.
• W2896700799 sameAs 2896700799 @default.
• W2896700799 citedByCount "11" @default.
• W2896700799 countsByYear W28967007992020 @default.
• W2896700799 countsByYear W28967007992021 @default.
• W2896700799 countsByYear W28967007992022 @default.
• W2896700799 countsByYear W28967007992023 @default.
• W2896700799 crossrefType "journal-article" @default.
• W2896700799 hasAuthorship W2896700799A5008124413 @default.
• W2896700799 hasAuthorship W2896700799A5009065617 @default.
• W2896700799 hasAuthorship W2896700799A5018500823 @default.
• W2896700799 hasAuthorship W2896700799A5019197153 @default.
• W2896700799 hasAuthorship W2896700799A5022422153 @default.
• W2896700799 hasAuthorship W2896700799A5023282277 @default.
• W2896700799 hasAuthorship W2896700799A5025120810 @default.
• W2896700799 hasAuthorship W2896700799A5026548827 @default.
• W2896700799 hasAuthorship W2896700799A5030332289 @default.
• W2896700799 hasAuthorship W2896700799A5033795704 @default.
• W2896700799 hasAuthorship W2896700799A5034692104 @default.
• W2896700799 hasAuthorship W2896700799A5049294543 @default.
• W2896700799 hasAuthorship W2896700799A5053880366 @default.
• W2896700799 hasAuthorship W2896700799A5073189857 @default.
• W2896700799 hasAuthorship W2896700799A5079047996 @default.
• W2896700799 hasAuthorship W2896700799A5079638740 @default.
• W2896700799 hasAuthorship W2896700799A5080783554 @default.
• W2896700799 hasAuthorship W2896700799A5087491297 @default.
• W2896700799 hasAuthorship W2896700799A5089861374 @default.
• W2896700799 hasAuthorship W2896700799A5091426116 @default.
• W2896700799 hasBestOaLocation W28967007991 @default.
• W2896700799 hasConcept C121608353 @default.
• W2896700799 hasConcept C126322002 @default.
• W2896700799 hasConcept C141341695 @default.
• W2896700799 hasConcept C143998085 @default.
• W2896700799 hasConcept C203092338 @default.
• W2896700799 hasConcept C2777701055 @default.
• W2896700799 hasConcept C2779984678 @default.
• W2896700799 hasConcept C2780110267 @default.
• W2896700799 hasConcept C31760486 @default.
• W2896700799 hasConcept C530470458 @default.
• W2896700799 hasConcept C535046627 @default.
• W2896700799 hasConcept C71924100 @default.
• W2896700799 hasConceptScore W2896700799C121608353 @default.
• W2896700799 hasConceptScore W2896700799C126322002 @default.
• W2896700799 hasConceptScore W2896700799C141341695 @default.
• W2896700799 hasConceptScore W2896700799C143998085 @default.
• W2896700799 hasConceptScore W2896700799C203092338 @default.
• W2896700799 hasConceptScore W2896700799C2777701055 @default.
• W2896700799 hasConceptScore W2896700799C2779984678 @default.
• W2896700799 hasConceptScore W2896700799C2780110267 @default.
• W2896700799 hasConceptScore W2896700799C31760486 @default.
• W2896700799 hasConceptScore W2896700799C530470458 @default.
• W2896700799 hasConceptScore W2896700799C535046627 @default.
• W2896700799 hasConceptScore W2896700799C71924100 @default.
• W2896700799 hasLocation W28967007991 @default.
• W2896700799 hasOpenAccess W2896700799 @default.
• W2896700799 hasPrimaryLocation W28967007991 @default.
• W2896700799 hasRelatedWork W1551938148 @default.
• W2896700799 hasRelatedWork W1852785632 @default.
• W2896700799 hasRelatedWork W2097545995 @default.
• W2896700799 hasRelatedWork W2130626169 @default.
• W2896700799 hasRelatedWork W2169374891 @default.
• W2896700799 hasRelatedWork W2297790284 @default.
• W2896700799 hasRelatedWork W2554176272 @default.
• W2896700799 hasRelatedWork W2886193299 @default.
• W2896700799 hasRelatedWork W3089163820 @default.
• W2896700799 hasRelatedWork W3185728978 @default.
• W2896700799 hasVolume "29" @default.
• W2896700799 isParatext "false" @default.
• W2896700799 isRetracted "false" @default.
• W2896700799 magId "2896700799" @default.

• next